1 |
Solomon, M. and Muro, S. (2017) Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives. Adv. Drug Deliv. Rev. 118, 109-134.
DOI
|
2 |
Song, X., Zhong, L., Lyu, N., Liu, F., Li, B., Hao, Y., Xue, Y., Li, J., Feng, Y., Ma, Y., Hu, Y. and Zhu, B. (2019) Inulin can alleviate metabolism disorders in ob/ob mice by partially restoring leptin-related pathways mediated by gut microbiota. Genomics Proteomics Bioinformatics 17, 64-75.
DOI
|
3 |
Stein, E. A., Honarpour, N., Wasserman, S. M., Xu, F., Scott, R. and Raal, F. J. (2013) Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128, 2113-2120.
DOI
|
4 |
Xiao, C., Rossignol, F., Vaz, F. M. and Ferreira, C. R. (2021) Inherited disorders of complex lipid metabolism: a clinical review. J. Inherit. Metab. Dis. 44, 809-825.
DOI
|
5 |
Dibaise, J. K., Zhang, H., Crowell, M. D., Krajmalnik-Brown, R., Decker, G. A. and Rittmann, B. E. (2008) Gut microbiota and its possible relationship with obesity. Mayo Clin. Proc. 4, 460-469.
|
6 |
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., Sasapu, A., Beebe, A., Patil, N., Musham, C. K., Lohani, G. P. and Mirza, W. (2017) Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front. Endocrinol. 8, 6.
|
7 |
Coppens, I., Asai, T. and Tomavo, S. (2014) Chapter 8 - Biochemistry and metabolism of Toxoplasma gondii: carbohydrates, lipids and nucleotides. In Toxoplasma Gondii (2nd ed.) (L. M. Weiss and K. Kim, Eds.), pp. 257-295. Academic Press.
|
8 |
Denisenko, Y. K., Kytikova, O. Y., Novgorodtseva, T. P., Antonyuk, M. V., Gvozdenko, T. A. and Kantur, T. A. (2020) Lipid-induced mechanisms of metabolic syndrome. J. Obes. 2020, 5762395.
|
9 |
Fernandez, L. P., Gomez, de Cedron, M., Ramirez de Molina, A. (2020) Alterations of lipid metabolism in cancer: implications in prognosis and treatment. Front. Oncol. 10, 577420.
DOI
|
10 |
Estruch, R., Ros, E., Salas-Salvado, J., Covas, M. I., Corella, D., Aros, F., Gomez-Gracia, E., Ruiz-Gutierrez, V., Fiol, M., Lapetra, J., Lamuela-Raventos, R. M., Serra-Majem, L., Pinto, X., Basora, J., Munoz, M. A., Sorli, J. V., Martinez, J. A., and Martinez-Gonzalez, M. A. (2013) Primary prevention of cardiovascular disease with a mediterranean diet. N Engl J Med 368,1279-1290.
DOI
|
11 |
Frayn, K. N., Coppack, S. W., Humphreys, S. M., Clark, M. L. and Evans, R. D. (1993) Periprandial regulation of lipid metabolism in insulin-treated diabetes mellitus. Metabolism 42, 504-510.
DOI
|
12 |
McGowan, M. P., Hosseini Dehkordi, S. H., Moriarty, P. M. and Duell, P. B. (2019) Diagnosis and treatment of heterozygous familial hypercholesterolemia. J. Am. Heart Assoc. 8, e013225.
DOI
|
13 |
Tian, L. and Yu, X. (2015) Lipid metabolism disorders and bone dysfunction-interrelated and mutually regulated (review). Mol. Med. Rep. 12, 783-794.
DOI
|
14 |
Bagger, Y. Z., Tanko, L. B., Alexandersen, P., Qin, G. and Christiansen, C.; Prospective epidemiological risk factors study group (2006) Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J. Intern. Med. 259, 598-605.
DOI
|
15 |
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgozoglu, L., Nordestgaard, B. G., Bruckert, E., De Backer, G., Krauss, R. M., Laufs, U., Santos, R. D., Hegele, R. A., Hovingh, G. K., Leiter, L. A., Mach, F., Marz, W., Newman, C. B., Wiklund, O., Jacobson, T. A., Catapano, A. L., Chapman, M. J. and Ginsberg, H. N.; European Atherosclerosis Society Consensus Panel (2015) Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012-1022.
DOI
|
16 |
Tracey, T. J., Steyn, F. J., Wolvetang, E. J. and Ngo, S. T. (2018) Neuronal lipid metabolism: multiple pathways driving functional outcomes in health and disease. Front. Mol. Neurosci. 11, 10.
DOI
|
17 |
Trebaticka, J., Dukat, A., Durackova, Z. and Muchova, J. (2017) Cardiovascular diseases, depression disorders and potential effects of omega-3 fatty acids. Physiol. Res. 66, 363-382.
|
18 |
Stone, N. J. (1994) Secondary causes of hyperlipidemia. Med. Clin. North Am. 78, 117-141.
DOI
|
19 |
Catapano, A. L., Reiner, Z., De Backer, G., Graham, I., Taskinen, M. R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M., Durrington, P., Erdine, S., Halcox, J., Hobbs, R., Kjekshus, J., Filardi, P. P., Riccardi, G., Storey, R. F. and Wood, D.; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS) (2011) ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217, 3-46.
DOI
|
20 |
Kromhout, D., Giltay, E. J. and Geleijnse, J. M.; Alpha Omega Trial Group (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 363, 2015-2026.
DOI
|
21 |
Verma, N. (2017) Introduction to hyperlipidemia and its treatment: a review. Int. J. Curr. Pharm. Res. 9, 6-14.
DOI
|
22 |
Azhar, S. (2010) Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 6, 657-691.
DOI
|
23 |
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H., Blom, D., Eriksson, M., Dent, R., Wasserman, S. M., Huang, F., Xue, A., Albizem, M., Scott, R. and Stein, E. A. (2014) Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J. Am. Coll. Cardiol. 63, 1278-1288.
DOI
|
24 |
Taskinen, M. R., Lahdenpera, S. and Syvanne, M. (1996) New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann. Med. 28, 335-340.
DOI
|
25 |
Rysman, E., Brusselmans, K., Scheys, K., Timmermans, L., Derua, R., Munck, S., Van Veldhoven, P. P., Waltregny, D., Daniels, V. W., Machiels, J., Vanderhoydonc, F., Smans, K., Waelkens, E., Verhoeven, G. and Swinnen, J. V. (2010) De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70, 8117-8126.
DOI
|
26 |
Yuan, G., Al-Shali, K. Z. and Hegele, R. A. (2007) Hypertriglyceridemia: its etiology, effects and treatment. Can. Med. Assoc. J. 176, 1113-1120.
DOI
|
27 |
Ophardt, C. E. (2003) Overview of lipid function. In Virtual ChemBook. Elmhurst College. Available from: http://chemistry.elmhurst.edu/vchembook/620fattyacid.html/.
|
28 |
Yue, S., Li, J., Lee, S. Y., Lee, H. J., Shao, T., Song, B., Cheng, L., Masterson, T. A., Liu, X., Ratliff, T. L. and Cheng, J. X. (2014) Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 19, 393-406.
DOI
|
29 |
Pischon, T., Nothlings, U. and Boeing, H. (2008) Obesity and cancer. Proc. Nutr. Soc. 67, 128-145.
DOI
|
30 |
Ratnayake, W. M. N. and Galli, C. (2009) Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Ann. Nutr. Metab. 55, 8-43.
DOI
|
31 |
Shattat, G. F. A. (2014) Review article on hyperlipidemia: types, treatments and new drug targets. Biomed. Pharmacol. J. 7, 399-409.
DOI
|
32 |
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A. and Skene, A. M.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504.
DOI
|
33 |
Dias, S., Paredes, S. and Ribeiro, L. (2018) Drugs involved in dyslipidemia and obesity treatment: focus on adipose tissue. Int. J. Endocrinol. 4, 2637418.
|
34 |
Fahy, E., Cotter, D., Sud, M. and Subramaniam, S. (2011) Lipid classification, structures and tools. Biochim. Biophy. Acta 1811, 637-647.
DOI
|
35 |
Natesan, V. and Kim, S. J. (2021) Diabetic nephropathy - a review of risk factors, progression, mechanism, and dietary management. Biomol. Ther. (Seoul) 29, 365-372.
DOI
|
36 |
Lattimer, J. M. and Haub, M. D. (2010) Effects of dietary fiber and its components on metabolic health. Nutrients 2, 1266-1289.
DOI
|
37 |
Garcia, M., Mulvagh, S. L., Bairey Merz, C. N., Buring, J. E. and Manson, J. E. (2016) Cardiovascular disease in women: clinical perspectives. Circ. Res. 118, 1273-1293.
DOI
|
38 |
Ahmed, S., Shah, P. and Ahmed, O. (2021) Biochemistry, lipids. In: StatPearls, pp. 11-19. StatPearls Publishing, Treasure Island.
|
39 |
Alves-Bezerra, M. and Cohen, D. E. (2017) Triglyceride metabolism in the liver. Compr. Physiol. 8, 1-8.
|
40 |
Alwarawrah, Y., Hughes, P., Loiselle, D., Carlson, D. A., Darr, D. B., Jordan, J. L., Xiong, J., Hunter, L. M., Dubois, L. G., Thompson, J. W., Kulkarni, M. M., Ratcliff, A. N., Kwiek, J. J. and Haystead, T. A. (2016) Fasnall, a selective FASN inhibitor, shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer. Cell Chem. Biol. 23, 678-688.
DOI
|
41 |
Nilsson, P. M., Tuomilehto, J. and Ryden, L. (2019) The metabolic syndrome - what is it and how should it be managed? Eur. J. Prev. Cardiol. 26, 33-46.
DOI
|
42 |
Novgorodtseva, T. P., Karaman, Y. K., Zhukova, N. V., Lobanova, E. G., Antonyuk, M. V. and Kantur, T. A. (2011) Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome. Lipids Health Dis. 10, 82.
DOI
|
43 |
Pahan, K. (2006) Lipid-lowering drugs. Cell. Mol. Life Sci. 63, 1165-1178.
DOI
|
44 |
Parhofer, K. G. (2016) The treatment of disorders of lipid metabolism. Dtsch. Arztebl. Int. 113, 261-268.
|
45 |
Athenstaedt, K. and Daum, G. (2006) The life cycle of neutral lipids: synthesis, storage and degradation. Cell. Mol. Life Sci. 63, 1355-1369.
DOI
|
46 |
Amalan, V. and Vijayakumar, N. (2015) Antihyperglycemic effect of p-coumaric acid on streptozotocin induced diabetic rats. Indian J. Appl. Res. 5, 10-13.
|
47 |
Amalan, V., Vijayakumar, N. and Ramakrishnan, A. (2015) P-Coumaric acid regulates blood glucose and antioxidant levels in streptozotocin induced diabetic rats. J. Chem. Pharm. Res. 7, 831-839.
|
48 |
Arumugam, R. and Natesan, V. (2017) Urea cycle pathway targeted therapeutic action of naringin against ammonium chloride induced hyperammonemic rats. Biomed. Pharmacother. 94, 1028-1037.
DOI
|
49 |
Bazinet, R. P. and Laye, S. (2014) Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat. Rev. Neurosci. 15, 771-785.
DOI
|
50 |
Fahy, E., Subramaniam, S., Brown, H. A., Glass, C. K., Merrill, A. H., Jr., Murphy, R. C., Russell, D. W., Seyama, Y., Shaw, W., Shimizu, T., Spener, F., van Meer, G., VanNieuwenhze, M. S., White, S. H., Witztum, J. L. and Dennis, E. A. (2005) A comprehensive classification system for lipids. J. Lipid Res. 46, 839-861.
DOI
|
51 |
Fredrickson, D. S. and Lees, R. S. (1965) Editorial: a system for phenotyping hyperlipoproteinemia. Circulation 31, 321-327.
DOI
|
52 |
Goldberg, I. J., Trent, C. M. and Schulze, P. C. (2012) Lipid metabolism and toxicity in the heart. Cell Metab. 15, 805-812.
DOI
|
53 |
Huang, C. and Freter, C. (2015) Lipid metabolism, apoptosis and cancer therapy. Int. J. Mol. Sci. 16, 924-949.
DOI
|
54 |
Joynt, K. E., Whellan, D. J. and Oconnor, C. M. (2003) Depression and cardiovascular disease: mechanisms of interaction. Biol. Psychiatry 54, 248-261.
DOI
|
55 |
Castle, J. C., Hara, Y., Raymond, C. K., Garrett-Engele, P., Ohwaki, K., Kan, Z., Kusunoki, J. and Johnson, J. M. (2009) ACC2 is expressed at high levels in human white adipose and has an isoform with a novel N-terminus. PLoS ONE 4, e4369.
DOI
|
56 |
Waller, J. R. and Waller, D. G. (2014) Drugs for lipid disorders, antiplatelet drugs and fibrinolytics. Medicine 42, 544-548.
DOI
|
57 |
Wu, L., Piotrowski, K., Rau, T., Waldmann, E., Broedl, U. C., Demmelmair, H., Koletzko, B., Stark, R. G., Nagel, J. M., Mantzoros, C. S. and Parhofer, K. G. (2014) Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial. Metabolism 63, 382-391.
DOI
|
58 |
Yan, J. and Horng, T. (2020) Lipid metabolism in regulation of macrophage functions. Trends Cell Biol. 30, 979-989.
DOI
|
59 |
Burdon, K. P., Langefeld, C. D., Beck, S. R., Wagenknecht, L. E., Carr, J. J., Freedman, B. I., Herrington, D. and Bowden, D. W. (2005) Association of genes of lipid metabolism with measures of subclinical cardiovascular disease in the Diabetes Heart Study. J. Med. Genet. 42, 720-724.
DOI
|
60 |
Butte, N. F. (2000) Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am. J. Clin. Nutr. 71, 1256S-1261S.
DOI
|
61 |
Glass, C. K. and Olefsky, J. M. (2012) Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15, 635-645.
DOI
|
62 |
Grundy, S. M. (2009) Advancing drug therapy of the metabolic syndrome. Nat. Rev. Drug Discov. 8, 341.
DOI
|
63 |
Huang, J., Borensztajn, J. and Reddy, J. K. (2011) Hepatic lipid metabolism. In: Molecular Pathology of Liver Diseases. Molecular Pathology Library, Vol. 5 (S. Monga, Ed.), pp. 133-146. Springer, Boston.
|
64 |
Hur, K. Y. and Lee, M. (2015) Gut microbiota and metabolic disorders. Diabetes Metab. J. 39, 198-203.
DOI
|
65 |
Knopp, R. H. (1999) Drug treatment of lipid disorders. N. Engl. J. Med. 341, 498-511.
DOI
|
66 |
Malhotra, A., Shafiq, N., Arora, A., Singh, M., Kumar, R. and Malhotra, S. (2014) Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst. Rev. 2014, CD001918.
|
67 |
Lesniak, W., Bala, M. M., Placzkiewicz-Jankowska, E., Topor-Madry, R., Jankowski, M., Sieradzki, J. and Banasiak, W.; ARETAEUS2 Study Group (2015) Cardiovascular risk management in type 2 diabetes of more than 10-year duration: Results of Polish ARETAEUS2-Grupa Study. Cardiol. J. 22, 150-159.
DOI
|
68 |
Musso, G., Cassader, M., Paschetta, E. and Gambino, R. (2018) Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology 155, 282-302.e8.
DOI
|
69 |
Nelson, R. H. (2013) Hyperlipidemia as a risk factor for cardiovascular disease. Prim. Care 40, 195-211.
DOI
|
70 |
Lee, C. H., Olson, P. and Evans, R. M. (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144, 2201-2207.
DOI
|
71 |
Monnerie, S., Comte, B., Ziegler, D., Morais, J. A., Pujos- Guillot, E. and Gaudreau, P. (2020) Metabolomic and lipidomic signatures of metabolic syndrome and its physiological components in adults: a systematic review. Sci. Rep. 10, 669.
DOI
|
72 |
Nagy, K. and Tiuca, I.-D. (2017) Importance of fatty acids in physiopathology of human body. In Fatty Acids. IntechOpen. doi: 10.5772/67407.
DOI
|
73 |
Lark, D. S., Fisher-Wellman, K. H. and Neufer, P. D. (2012) High-fat load: mechanism(s) of insulin resistance in skeletal muscle. Int. J. Obes. Suppl. 2, S31-S36.
DOI
|
74 |
Church, C., Horowitz, M. and Rodeheffer, M. (2012) WAT is a functional adipocyte? Adipocyte 1, 38-45.
DOI
|
75 |
Arslan, N. (2014) Obesity, fatty liver disease and intestinal microbiota. World J. Gastroenterol. 44, 16452-16463.
DOI
|
76 |
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., Monsalvo, M. L., Tsirtsonis, K., Kim, J. B., Scott, R., Wasserman, S. M. and Stein, E. A.; DESCARTES Investigators (2014) A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl J. Med. 370, 1809-1819.
DOI
|
77 |
Cani, P. D., Delzenne, N. M., Amar, J. and Burcelin, R. (2008) Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol. Biol. 56, 305-309.
DOI
|
78 |
Di Mauro, S., Trevisan, C. and Hays, A. (1980) Disorders of lipid metabolism in muscle. Muscle Nerve 3, 369-388.
DOI
|
79 |
Dogan, E. S. K., Dogan, B., Fentoglu, O. and Kirzioglu, F. Y. (2019) The role of serum lipoxin A4 levels in the association between periodontal disease and metabolic syndrome. J. Periodontal Implant Sci. 49, 105-113.
DOI
|
80 |
Quispe, R., Hendrani, A., Baradaran-Noveiry, B., Martin, S., Brown, E., Kulkarni, K., Banach, M., Toth, P. P., Brinton, E. A., Jones, S. R. and Joshi, P. (2019) Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7. Arch. Med. Sci. 15, 1195-1202.
DOI
|
81 |
Reckless, J. P. D. and Lawrence, J. M. (2003) Hyperlipidemia (hyperlipidaemia). In Encyclopedia of Food Sciences and Nutrition (2nd ed.), pp. 3183-3192. Academic Press.
|
82 |
Rosca, M. G., Vazquez, E. J., Chen, Q., Kerner, J., Kern, T. S. and Hoppel, C. L. (2012) Oxidation of fatty acids is the source of increased mitochondrial reactive oxygen species production in kidney cortical tubules in early diabetes. Diabetes 61, 2074-2083.
DOI
|
83 |
Saudek, C. D. and Eder, H. A. (1979) Lipid metabolism in diabetes mellitus. Am. J. Med. 66, 843-852.
DOI
|
84 |
Schonfeld, G. (1990) Inherited disorders of lipid transport. Endocrinol. Metab. Clin. North Am. 19, 229-257.
DOI
|
85 |
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Boren, J., Bruckert, E., Catapano, A. L., Descamps, O. S., Hovingh, G. K., Humphries, S. E., Kovanen, P. T., Masana, L., Pajukanta, P., Parhofer, K. G., Raal, F. J., Ray, K. K., Santos, R. D., Stalenhoef, A. F., Stroes, E., Taskinen, M. R., Tybjaerg-Hansen, A., Watts, G. F. and Wiklund, O.; European Atherosclerosis Society Consensus Panel (2014) The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2, 655-666.
DOI
|
86 |
Sparrow, C. P., Burton, C. A., Hernandez, M., Mundt, S., Hassing, H., Patel, S., Rosa, R., Hermanowski-Vosatka, A., Wang, P. R., Zhang, D., Peterson, L., Detmers, P. A., Chao, Y. S. and Wright, S. D. (2001) Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 21, 115-121.
DOI
|
87 |
Cena, H. and Calder, P. C. (2020) Defining a healthy diet: evidence for the role of contemporary dietary patterns in health and disease. Nutrients 12, 334.
DOI
|
88 |
Tocher, D. R. (2003) Metabolism and functions of lipids and fatty acids in teleost fish. Rev. Fish. Sci. 11, 107-184.
DOI
|
89 |
Uttaro, A. (2006) Biosynthesis of polyunsaturated fatty acids in lower eukaryotes. IUBMB Life 58, 563-571.
DOI
|
90 |
Wu, L. and Parhofer, K. G. (2014) Diabetic dyslipidemia. Metabolism 63, 1469-1479.
DOI
|